HOME >> MEDICINE >> NEWS
Studies suggest investigational agent reduces disease activity in MS

BOSTON A new drug under investigation shows a reduction in disease activity in multiple sclerosis (MS), according to two studies that will be presented at the American Academy of Neurology's 59th Annual Meeting in Boston, April 28 May 5, 2007. The drug reduced disease activity as indicated by MRI scans.

Both of the studies involved people with the relapsing-remitting form of MS, where symptoms flare up and then subside. By 24 weeks, treatment with the drug rituximab reduced the number of areas of brain damage, or lesions, in people with MS and the number of relapses, or times when symptoms flare up, when compared with placebo.

Rituximab is a therapeutic antibody that selectively targets and depletes a subset of immune cells called B-cells by targeting a specific protein on their surface.

"This is the first drug to target B-cells and may represent a potential new treatment strategy for relapsing-remitting MS," said study author Stephen Hauser, MD, of the University of California, San Francisco, and a member of the American Academy of Neurology. "While these are early stage clinical trials, these results are exciting, because the current drugs available for MS are only partially effective in reducing disease activity and preventing exacerbations. New and more effective treatments for MS are sorely needed, especially for people who do not adequately respond to currently available medications. These data are also important because they demonstrate that B-cells, which are the precursors of antibody-producing cells, play an essential role in mediating relapses of MS."

In the first study, a randomized, placebo-controlled trial, 69 people were given two infusions of rituximab two weeks apart and 35 were given a placebo. The participants were followed for six months. Those given rituximab had approximately 90 percent fewer brain lesions than those given placebo. During the six-month period, 58 percent fewer of those taking the d
'"/>

Contact: Angela Babb
ababb@aan.com
651-695-2789
American Academy of Neurology
1-May-2007


Page: 1 2 3

Related medicine news :

1. Studies show antidepressants not linked to birth defects
2. Studies show role of age, gender, race and weight on cancer risk and treatment
3. Studies highlight advances in diagnosis, medical therapy
4. Studies highlight real world use, safety of drug-eluting stents
5. Studies led by Rhode Island Hospital confirm safety and efficacy
6. Studies identify food sources of disease and drug resistance
7. Studies provide new evidence on risks associated with Cox-2 inhibitors and NSAIDs
8. Studies highlight need to monitor heart function in breast cancer patients
9. Studies examine physician disclosure of medical errors
10. Studies indicate medication can be an effective therapy for smoking cessation
11. Studies evaluating health effects of dental amalgam fillings in children confirm safety

Post Your Comments:
(Date:7/30/2014)... 2014 Within weeks freshman will begin to pour ... hopes this will be a time of growth and the start ... pause; it may not be as easy as it looks. Some ... switch their major at least once and many will switch two ... the costs are exacerbated when switching in the later years of ...
(Date:7/30/2014)... 2014 Throughout the month of August, ... oral cancer screenings. Using a new technological tool called ... the disease in its early stages. , Oral cancer ... sinuses, throat and other areas in and around the ... and Ends Results (SEER) program, 30 percent of oral ...
(Date:7/30/2014)... Cucamonga, CA (PRWEB) July 30, 2014 Serial ... learning how to make millions. However, like most people, in ... Determined to find a better way, Paul carefully studied ... wealth and those who do not. Based on the knowledge ... to not only improve his life and health, but also ...
(Date:7/30/2014)... Dennis Thompson HealthDay Reporter ... with depression are more likely to develop dementia, but researchers ... relationship between the two. Specifically, they haven,t been able ... -- does depression help bring on dementia, or does dementia ... online July 30 in the journal Neurology sheds ...
(Date:7/30/2014)... Ann Arbor, MI (PRWEB) July 30, 2014 ... Madrid vs. Manchester United Tickets in Ann Arbor, MI on ... in the world of international football will be competing on American ... at “The Big House,” in Ann Arbor, Mich. The home of ... venue is one of the most prestigious in all of American ...
Breaking Medicine News(10 mins):Health News:Advice to College Freshman from Author Garrett Miller 2Health News:Advice to College Freshman from Author Garrett Miller 3Health News:Restore Dental Offers Complimentary Oral Cancer Screenings in August 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Scientists Shed Light on Link Between Depression, Dementia 2Health News:Scientists Shed Light on Link Between Depression, Dementia 3Health News:Manchester United vs. Real Madrid Tickets Ann Arbor: Ticket Down Slashes Ticket Prices for Real Madrid vs. ManU Guinness International Champions Cup Match 2Health News:Manchester United vs. Real Madrid Tickets Ann Arbor: Ticket Down Slashes Ticket Prices for Real Madrid vs. ManU Guinness International Champions Cup Match 3Health News:Manchester United vs. Real Madrid Tickets Ann Arbor: Ticket Down Slashes Ticket Prices for Real Madrid vs. ManU Guinness International Champions Cup Match 4
(Date:7/30/2014)... 30, 2014   Unique Pizza and Subs ... Pink: UPZS), a Delaware Corporation, is pleased to ... Larasan Pharmaceutical Corporation ("Larasan"), a nature-based pharmaceutical company that ... agreement, US-based Larasan will work with Unique to ... through Larasan,s vast distribution network throughout ...
(Date:7/30/2014)... Germany , July 30, 2014 /PRNewswire/ ... use and computer-assisted ("robotic") colonoscopy system, today announced the ... recognized medical device executive, as a new member of ... a highly respected global visionary in the medical device ... President and Chief Executive Officer at Given Imaging Ltd. ...
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... of alirocumab in people with hypercholesterolemia met their primary ... in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared ... monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
Breaking Medicine Technology:Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8
Cached News: